Compare Schwab US Dividend Equity ETF (SCHD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Schwab US Dividend Equity ETFTrade

State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Schwab US Dividend Equity ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Schwab US Dividend Equity ETF trades at $34.2, while State Street SPDR S&P Biotech ETF trades at $158.22. Which is the better fit depends on your goals.

	SCHD	XBI
Sector	Broad Market / Factor	Broad Market / Factor
52-Week High	$34.27	$164.28
52-Week Low	$26.44	$86.92

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

SCHD

SCHD ETF's index reshuffle caused unexpected high taxable distributions in 2024, hitting taxable accounts hard.24/7 Wall Street · 16 hours agoNeutral Vanguard High Dividend Yield ETF lags S&P 500 by $141K over 10 years despite dividends.24/7 Wall Street · 1 day agoBearish WisdomTree U.S. Total Dividend ETF (DTD) rated 'hold' for balanced factors but overlaps 57% with S&P 500 ETFs.Seeking Alpha · 1 day agoNeutral View details →

XBI

View details →

About Schwab US Dividend Equity ETF

SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.